Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A.

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)

In patients who switched from a standard half-life FVIII to Adynovate prophylaxis in routine clinical practice, bleeding control was generally improved or maintained, with a lower infusion frequency and factor consumption in most patients.

Keyphrases

clinical practice
end stage renal disease

ejection fraction
newly diagnosed

peritoneal dialysis
atrial fibrillation

patient reported outcomes